The interplay between anticancer challenges and the microbial communities from the gut

Eur J Clin Microbiol Infect Dis. 2022 May;41(5):691-711. doi: 10.1007/s10096-022-04435-2. Epub 2022 Mar 30.

Abstract

Cancer being an increasing burden on human health, the use of anticancer drugs has risen over the last decades. The physiological effects of these drugs are not only perceived by the host's cells but also by the microbial cells it harbors as commensals, notably the gut microbiota. Since the early '50 s, the cytotoxicity of anticancer chemotherapy was evaluated on bacteria revealing some antimicrobial activities that result in an established perturbation of the gut microbiota. This perturbation can affect the host's health through dysbiosis, which can lead to multiple complications, but has also been shown to have a direct effect on the treatment efficiency.We, therefore, conducted a review of literature focusing on this triangular relationship involving the microbial communities from the gut, the host's disease, and the anticancer treatment. We focused specifically on the antimicrobial effects of anticancer chemotherapy, their impact on mutagenesis in bacteria, and the perspectives of using bacteria-based tools to help in the diagnostic and treatment of cancer.

Keywords: Anticancer drugs; Gut microbiota; Microbiology; Mutagenesis; Oncology.

Publication types

  • Review

MeSH terms

  • Anti-Infective Agents*
  • Bacteria
  • Dysbiosis / microbiology
  • Gastrointestinal Microbiome* / physiology
  • Humans
  • Microbiota*
  • Neoplasms* / therapy

Substances

  • Anti-Infective Agents